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Purpose
Children with malignancies, including neuroblastoma
(NB), may present to their primary physician with com-
plaints that mimic those seen in systemic juvenile idio-
pathic arthritis (sJIA). The purpose of this investgation
was to identify significant distinctions between patients
with systemic JIA and neuroblastoma at the time of dis-
ease presentation.
Methods
A retrospective chart review was completed on all
patients less than age 18, between 1990 and 2009 at
Pennsylvania State University Children’s Hospital, with a
diagnosis of either sJIA or NB. The following variables
were identified at the time of presentation; gender, age,
race, time to diagnosis, presenting signs and symptoms,
neuroblastoma stage, LDH, uric acid, sedimentation rate,
CRP, platelet count, hemoglobin, peripheral white blood
cell count, percentage of neutrophils and lymphocytes,
ferritin, and d-dimer. Other categorical information
included whether or not the patients had gait disturbance
or extremity pain, fever, rash, abdominal mass, arthritis,
fatigue, or weight loss. Individual logistic regression mod-
els were evaluated for each variable, with sJIA or NB as
the outcome. Given that patients with NB and extremity
pain may be referred to orthopedics or rheumatology
first, instead of a timely referral to hematology/oncology,
a subgroup analysis was completed for those patients.
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Table 1 Presentation characteristics of SJIA versus NB patients
Variables sJIA (65) Neuroblastoma (89)
Age (years) 7.2 ± 4.7 3.0 ± 3.5 <0.0001
Gender Famle 51% Female 42% 0.26
Male 49% Male 58%
Race White 91% White 85% 0.86
Black 6% Black 7%
Hispanic 3% Hispanic 3%
Other 5%
Fever present (0=no, 1=yes) 45/45 (100%) 12/71 (18%) <0.0001
Time to diagnosis (months) 1.5 (65) 1.2 (78) 0.18
Arthritis 51/65 (78%) 1/71 (1%) <0.0001
Rash 53/64 (83%) 2/71 (3%) <0.0001
Abdominal mass 1/65 (2%) 29/71 (41%) 0.0001
Weight loss 11/65 (17%) 5/71 (7%) 0.07
Gait disturbance or extremity pain 45/65 (41%) 13/73 (18%) <0.0001
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Results
There was a total of 65 sJIA and 89 NB patients. Demo-
graphically, sJIA patients were significantly older (7.2 vs.
3.0 years of age; p<0.0001). Symptomatically, the sJIA
patients had fever, rash,arthritis, and extemity pain or
gait disturbance (41% vs. 18%) more frequently
(p<0.0001 for all). Laboratories were also significantly
different between the groups. NB patients had higher
LDH and uric acid levels, while sJIA patients had higher
platelet counts, total peripheral WBC, had relative neu-
trophilia (p<0.0001 for all), and had higher ferritin levels
than the NB patients (p=0.001), see Table 1. In the sub-
group of 58 children with extremity pain or gait distur-
bance, 45 (78%) had sJIA and 13 (22%) had NB; see
Table 2. NB patients had higher LDH (p=0.01) and
lower hgb levels (p=0.003), while sJIA patients had a
relative neutrophilia (76% versus 51%; p<0.0001).
Conclusion
There are significantly different demographic, presenting
symptoms, and laboratories at the time of presentation
of patients who are ultimately diagnosed with sJIA or
NB. In particular, there are discerning laboratories that
may help facilitate an appropriate and timely referal to
oncology when extremity pain or gait disturbance are
among the intial signs and symptoms.
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Table 1 Presentation characteristics of SJIA versus NB patients (Continued)
Neuroblastoma stage n/a Stage 1 = 19/62 (31%) n/a
Stage 2 = 3/62 (5%)
Stage 3 = 9/62(14%)
Stage 4 =31/62 (50%)
LDH (units/L) 637 ± 530 (35) 1842 ± 2410 (46) 0.005
Uric Acid (mg/dL) 3.3 ± 1.2 (22) 5.1 ± 2.9 (34) 0.005
Crp (mg/dL) 14.9 ± 25.3 (26) 10.2 ± 7.2 (4) 0.71
ESR (mm/hr) 81.6 ± 36.3 (58) 61.7 ± 46.0 (13) 0.09
PLT count 464,016 ± 173,148 (62) 327,419 ± 136,488 (62) <0.00001
WBC 18,881 ± 11,449 (63) 10,484 ± 5,892 (68) <0.00001
HGB (g.dL) 10.2 ± 1.80 (62) 10.3 ± 2.46 (67) 0.97
Neurtophil % 73 ± 14 (57) 0.49 ± 0.17 (64) <0.00001
Lymphocyte % 17 ± 10 (47) 40 ± 17 (64) <0.00001
Ferntin (ng/mL) 4,016 ± 6, 135 (50) 159 ± 205 (29) 0.001
D-Dimer elevated 34/36 (94%) 2/2 (100%) 0.73
Aldolase 15.6 ± 11.4 (28) 8.85 ± 1.01 (2) 0.42
Table 2 Laboratory values for sJIA and NB subjects with
gait disturbance or extremity pain
Laboratory sJIA NB p-value
LDH 625 ± 522 (28) 1365 ± 1073 (9) 0.01
Uric Acid 3.2 ± 1.1 (20) 4.0 ± 1.2 (8) 0.14
CRP 9.9 ± 7.8 (22) 10.2 ± 7.3 (4) 0.95
ESR 84 ± 32 (42) 100 ± 32 (6) 0.24
Hgb 10.4 ± 1.7 (43) 8.5 ± 2.4 (12) 0.003
Neutrophil % 76 ± 12 (40) 51 ± 10 (11) <0.0001
Lympocyte % 15 ± 9 (40) 37 ± 12 (11) <0.0001
Ferritin 4554 ± 6890 (37) 555 ± 135 (3) 0.34
d-dimer abnormal 27/20 1/1 0.79
PTT 35 ± 6 (30) 31 ± 4 (5) 0.15
Aldolase 16 ± 2 (24) 9 ± 8 (2) 0.44
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